Clinical Trial Update: SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating SGLT2 inhibitors in transthyretin amyloid cardiomyopathy has completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• SGLT2 inhibitors (class)

Snippet

Sponsor: Columbia University | Conditions: Transthyretin Amyloid Cardiomyopathy | Phase 4 | Status: COMPLETED | Results posted: 2024-08-06